# Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy

> **NCT04904120** · PHASE1 · COMPLETED · sponsor: **Perspective Therapeutics** · enrollment: 7 (actual)

## Conditions studied

- Melanoma (Skin)
- Melanoma Stage IV
- Melanoma, Uveal
- Melanoma, Mucosal

## Interventions

- **DRUG:** [203Pb]VMT01
- **DRUG:** [68Ga]VMT02

## Key facts

- **NCT ID:** NCT04904120
- **Lead sponsor:** Perspective Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-05
- **Primary completion:** 2022-09-20
- **Final completion:** 2022-09-20
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04904120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04904120, "Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04904120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*